A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
Abstract Introduction Currently, only a few options are available for the treatment of patients with small‐cell lung cancer (SCLC) after the failure of first‐line platinum‐based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second‐line tr...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850268722141331456 |
|---|---|
| author | Yinghui Xu Xu Wang Chao Sun Zhiru Gao Hua He Shi Qiu Ye Guo Xiaohui Ma Junya Song Kewei Ma |
| author_facet | Yinghui Xu Xu Wang Chao Sun Zhiru Gao Hua He Shi Qiu Ye Guo Xiaohui Ma Junya Song Kewei Ma |
| author_sort | Yinghui Xu |
| collection | DOAJ |
| description | Abstract Introduction Currently, only a few options are available for the treatment of patients with small‐cell lung cancer (SCLC) after the failure of first‐line platinum‐based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second‐line treatment of advanced SCLC. Patients and Methods This prospective clinical trial recruited patients treated with apatinib plus second‐line chemotherapy until disease progression or intolerable toxicity. Logrank test power analysis was used for calculating samples. The primary endpoint was progression‐free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Results A total of 29/31 enrolled patients were available for response evaluation until October 2019. The ORR and DCR were 27.59% (8/29) and 96.55% (28/29), respectively. The median PFS and OS were 7.36 months and 14.16 months, respectively, indicating better efficacy compared with the standard second‐line chemotherapies. The most common adverse events (AEs) were neutropenia (41.94%, 13/31), followed by leucopenia (35.48%, 11/31) and thrombocytopenia (25.81%, 8/31). The grade 3–4 AEs occurred in 12 (38.71%) patients, of which neutropenia (19.35%, 6/31), leucopenia (9.68%, 3/31), and proteinuria (6.45%, 2/31) were most common. Patients receiving an initial dose of apatinib 250 mg had a better tolerance. Conclusion Antiangiogenic therapy plus chemotherapy had encouraging efficacy in advanced SCLC patients, which provides an insight into the current status of second‐line therapy in SCLC. |
| format | Article |
| id | doaj-art-ed2b7dc2fb5d45caa793a6ff9a3ee7ae |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-ed2b7dc2fb5d45caa793a6ff9a3ee7ae2025-08-20T01:53:22ZengWileyCancer Medicine2045-76342023-02-011232979298910.1002/cam4.5217A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancerYinghui Xu0Xu Wang1Chao Sun2Zhiru Gao3Hua He4Shi Qiu5Ye Guo6Xiaohui Ma7Junya Song8Kewei Ma9Cancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaCancer Center The First Hospital of Jilin University Changchun ChinaAbstract Introduction Currently, only a few options are available for the treatment of patients with small‐cell lung cancer (SCLC) after the failure of first‐line platinum‐based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second‐line treatment of advanced SCLC. Patients and Methods This prospective clinical trial recruited patients treated with apatinib plus second‐line chemotherapy until disease progression or intolerable toxicity. Logrank test power analysis was used for calculating samples. The primary endpoint was progression‐free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Results A total of 29/31 enrolled patients were available for response evaluation until October 2019. The ORR and DCR were 27.59% (8/29) and 96.55% (28/29), respectively. The median PFS and OS were 7.36 months and 14.16 months, respectively, indicating better efficacy compared with the standard second‐line chemotherapies. The most common adverse events (AEs) were neutropenia (41.94%, 13/31), followed by leucopenia (35.48%, 11/31) and thrombocytopenia (25.81%, 8/31). The grade 3–4 AEs occurred in 12 (38.71%) patients, of which neutropenia (19.35%, 6/31), leucopenia (9.68%, 3/31), and proteinuria (6.45%, 2/31) were most common. Patients receiving an initial dose of apatinib 250 mg had a better tolerance. Conclusion Antiangiogenic therapy plus chemotherapy had encouraging efficacy in advanced SCLC patients, which provides an insight into the current status of second‐line therapy in SCLC.https://doi.org/10.1002/cam4.5217angiogenesisapatinibsmall cell lung cancer (SCLC)targeted therapyVEGFR2 |
| spellingShingle | Yinghui Xu Xu Wang Chao Sun Zhiru Gao Hua He Shi Qiu Ye Guo Xiaohui Ma Junya Song Kewei Ma A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer Cancer Medicine angiogenesis apatinib small cell lung cancer (SCLC) targeted therapy VEGFR2 |
| title | A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer |
| title_full | A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer |
| title_fullStr | A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer |
| title_full_unstemmed | A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer |
| title_short | A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer |
| title_sort | phase ii study of antiangiogenic therapy apatinib plus chemotherapy as second line treatment in advanced small cell lung cancer |
| topic | angiogenesis apatinib small cell lung cancer (SCLC) targeted therapy VEGFR2 |
| url | https://doi.org/10.1002/cam4.5217 |
| work_keys_str_mv | AT yinghuixu aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT xuwang aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT chaosun aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT zhirugao aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT huahe aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT shiqiu aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT yeguo aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT xiaohuima aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT junyasong aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT keweima aphaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT yinghuixu phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT xuwang phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT chaosun phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT zhirugao phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT huahe phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT shiqiu phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT yeguo phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT xiaohuima phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT junyasong phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer AT keweima phaseiistudyofantiangiogenictherapyapatinibpluschemotherapyassecondlinetreatmentinadvancedsmallcelllungcancer |